Table 1.
Baseline characteristics.
| Variable | n = 272 |
|---|---|
| Sex, M:F | 169:103 |
| Median disease duration, months (IQR) | 13.2 (4.0–37.5) |
| Median age at referral, years (IQR) | 33 (24–41) |
| Montreal classification at Crohn’s disease diagnosis, n (%) | |
| L1: Ileal | 62 (22.8) |
| L2: Colonic | 45 (16.5) |
| L3: Ileocolonic | 165 (60.7) |
| Perianal lesion | 66 (24.3) |
| B1: Nonpenetrating nonstricturing | 153 (56.3) |
| B2: Stricturing | 86 (31.6) |
| B3: Penetrating | 33 (12.1) |
| Previous treatment, n (%) | |
| Prior surgery | 60 (23) |
| Prior medical treatment | |
| Steroid | 20 (7.4) |
| Immunosuppressives (azathioprine/6-mercaptopurine or methotrexate) | 14 (5.1) |
| Median erythrocyte sedimentation rate (IQR), mm/h | 35 (18–53) |
| Median C-reactive protein (IQR), mg/L | 11.03 (3.65–13.09) |
| Median Crohn’s Disease Activity Index (IQR) | 178 (114–250) |
IQR, interquartile range.